GVHD is a major complication in allogeneic SCT. Available GVHD models are mainly based on radiotherapy-conditioning and/or immune deficient mice. GVHD models based on chemotherapy-based regimens remain poorly studied, despite 50% of all transplantations being chemotherapy based. Our aim was to develop a GVHD model using chemotherapy as conditioning. Female BALB/c (H-2Kd) were conditioned with BU-CY and transplanted with 2 Â 10 7 BM and 3 Â 10 7 spleen cells from either C57BL/6 (H-2 Kb) mice (allogeneic setting) or from male BALB/c to serve as a control group for regimen-related toxicity and engraftment. GVHD manifestations and histopathological changes were evaluated. Chimerism and donor T cells presence in skin, intestine and liver were studied using FACS-, FISH analysis and immunohistochemistry. Allogeneic transplanted mice developed lethal GVHD starting from day þ 7 with both histological and clinical signs. Donor T cells accumulated in recipient skin and intestine with GVHD progression. BM-failure, apoptosis and T-lymphocyte infiltration into target organs were significantly higher in allogeneic when compared with the syngeneic group. No toxicity or GVHD signs were observed in the syngeneic setting. We report a mouse model of GVHD using BU-CY conditioning that represents the most common myeloablativeconditioning regimen in clinical SCT. This model can be utilized to study the role of conditioning on mechanisms underlying GVHD.
Introduction
Hematopoietic stem cell transplantation (HSCT) is a curative therapy for a wide variety of diseases, including hematological disorders, 1 metabolic diseases, immune deficiencies, autoimmune diseases and solid tumors. 2 However, the success of HSCT is limited by several complications such as acute GVHD (aGVHD), 3 graft rejection, veno-occlusive disease, infections and relapse. 4, 5 Mechanisms underlying the development of aGVHD are not fully understood. However, it is known that aGVHD emerges when donor T cells are activated by the host antigen-presenting cells, thereby inducing antigen-specific effector T cells. 6 The effector cells express high levels of tissue-specific adhesion and chemoattractant receptors, facilitating migration into target epithelial organs such as skin, intestine, lungs and liver. 7 The infiltration of effector cells into organs, is usually accompanied by non-specific release of pro-inflammatory cytokines for example, tumor necrosis factor, IL-1, IL-2 and IL-8, that have deleterious effects in the affected organs. 8 Apart from the histocompatibility disparities between donor and recipient, pre-transplant conditioning plays a crucial role in the development and severity of GVHD. 9, 10 Conditioning 11 has multiple functions in the recipient, including; the depletion of stem cells, 12 suppression of the host immune system and most importantly elimination of tumor cells. 13 A combination of CY and TBI was introduced into the clinic as a conditioning regimen about 30 years ago. 1, 14 During the early 1980s, an irradiation-free conditioning regimen consisting of BU and CY was introduced. 15 Comparative studies have shown that both conditioning regimens exhibit comparable potencies in their antileukemic and immunosuppressive effects. Furthermore, comparing both regimens showed no significant differences in the engraftment rates, survival, relapse and transplantation-related mortality. 16, 17 Animal models of HSCT are widely used to elucidate mechanisms underlying the development of aGVHD and further to provide strategies for its treatment. The majority of animal models of HSCT and GVHD are based on TBI as a conditioning regimen. On account of the variety of conditioning used in the clinical settings and because of the different mechanism of action of TBI and chemotherapy, available aGVHD models cannot cover different aspects of aGVHD in clinical settings since over 50% of the patients are conditioned with chemotherapy. There is an essential need for an animal model of aGVHD that mimics the clinical setting. Thus, in the present investigation, we introduce a mouse model of aGVHD where BU-CY was used as the conditioning regimen. The transplanted animals exhibited clinical and pathological manifestations, which completely fulfilled the criteria for aGVHD. The present model is reliable and can be utilized to elucidate the underlying mechanism for aGVHD developed after chemotherapy conditioning in allogeneic transplanted mice and to evaluate investigational therapies. ) mice (10-12 weeks old) were purchased from Scanbur (Sollentuna, Sweden). Mice were maintained under pathogen-free controlled conditions and 12-hr light/darkness. Animals had access to food and water ad libitum.
Materials and methods

Animals
Dose optimization BU and CY were obtained from Sigma (Stockholm, Sweden). BU was dissolved in DMSO (40 mg/ml) and CY in sterile water (10 mg/ml). Seven groups of female BALB/c and one group of C57BL/6 received IP doses of BU (20 or 25 mg/kg/day) for 4 days, followed by CY (100 or 150 mg/ kg/day) for 2 days. Days À1 and 0 were the resting and BMT days, respectively. Control group (BALB/c) was injected i.p. with vehicles only. The conditioning protocol and groups are summarized in Table 1 . All experiments described here were approved by the Ethical Committee for Animal Experimentation.
BMT
On day 0, donor male C57BL/6 and female BALB/c mice were killed by cervical dislocation. Bone marrow cells (BMC) were flushed from femur and tibia and single-cell suspension was prepared in RPMI-1640 (RPMI) containing FBS. Cells were then centrifuged and washed with RPMI. Donor spleens were disrupted in RPMI-containing FBS to form cell suspension. Splenocytes were passed through a 70 mm strainer, centrifuged and washed two times with RPMI. Recipient mice were injected i.v. with 20 Â 10 6 BMC combined with 30 Â 10 6 splenocytes from donors ( Table 1) .
Assessment of GVHD Recipient mice were monitored daily from conditioning start until the appropriate sampling day for the clinical manifestations of GVHD (for example, weight loss, hunched posture, poor activity, ruffled fur and loss of skin integrity). 18 The severity of each given symptom was scored from 0 to 2. The sum of the scores for all symptoms in each mouse (maximally 10) was used as an index of the severity and progression of GVHD. Each experiment was repeated 4-5 independent times.
Preparation of BM and spleen samples Recipient mice were killed at appropriate time points, and spleens and femurs were removed. Single cell suspensions of splenocytes and BMC's were prepared. Erythrocytes were lysed with ammonium chloride. The obtained single-cell suspensions were washed two times in PBS and resuspended in FACS buffer solution.
Isolation of epidermal immune cells
Epidermal immune cells in the skin were isolated as described earlier. 19 Briefly, pieces of skin (abdomen) were placed in a micro-tube containing 1 ml Dispase and incubated overnight at 4 1C. Epidermis was removed and the tissues were cut into small pieces. The samples were Table 1 Definition of study groups then digested in Dulbecco's modified Eagle's medium containing HEPES, DNase, collagenase D and hyaluronidase at 37 1C for 1.5 h. Thereafter, they were filtered through a 70 mm strainer to obtain single-cell suspensions.
Isolation of small intestine intraepithelial lymphocytes
Intestinal lymphocytes (intraepithelial) were isolated as described elsewhere. 20 Briefly, the small intestine was dissected and the lumen washed with cold PBS-2% FBS. The intestine was cut and placed in an Erlenmeyer flask containing PBS-FBS-EDTA. The flask was incubated for 20 min at 37 1C with stirring. After 15 s of vigorous vortex the supernatant was filtered and collected.
Preparation of blood samples for flow cytometry At different time points, peripheral blood samples (80 ml) were taken from a small incision in the tail and collected in tubes containing 200 ml PBS-EDTA. Blood was incubated with FC-blocker for 15 min at 4 1C and then stained with a panel of fluorochrome-conjugated mAbs. Erythrocytes were lysed and the stained cells were washed two times with FACS buffer and analyzed using FACSCalibur (BD Systems, San Jose, CA, USA). Analysis and detection of chimerism using fluorescence in situ hybridization (FISH) At days þ 7, þ 14, þ 21, þ 90 and þ 120, BM and spleen cell suspensions were applied onto slides using cytocentrifugation (25 000-50 000 cells/slide). FISH analysis was performed to detect the Y-chromosome as described earlier. 21 Briefly the cell nucleus was digested in HCl and pepsin. The probe, a total paint CY3-labeled mouse chromosome-Y DNA, was applied to the target area that simultaneously was denatured in a HYBrite chamber. The slides were washed, air-dried and counterstained with VectaShield DAPI (4 0 ,6-diamidine-2-phenylidole-dihydrochloride)/antifade. Signal spot counting of Y-chromosome was performed using a Nikon Eclipse-E800 fluorescence microscope. For documentation, an Olympus BH-2 microscope connected to CytoVision image system (Applied Imaging International Ltd, Newcastle-upon, Tyre, UK) was used.
Immunofluorescent staining and FACS analysis
Histology and Immunohistochemistry
Tissue samples were fixed in formalin for 24-h, transferred to 70% ethanol, dehydrated and embedded in paraffin. Immunohistochemical detection of CD3epsilon and cleaved Caspase-3 was performed using rabbit monoclonal antibodies, SP7 (Labvision, Fremont, CA, USA) and 5A1 (Cell Signalling Technology, Danvers, MA, USA), respectively. Briefly 4-5 mm sections were deparaffinized. Antigen retrieval was performed in a 2100 retriever and Buffer-A according to the manufacturer's instructions. Slides were rinsed, treated with H 2 O 2 in methanol and blocked by goat serum in Trisbuffer. Primary antibodies were diluted in the blocking solution and applied at 4 1C overnight. After rinsing in Tris-buffer, a biotin-labelled secondary anti-rabbit antibody was applied. Sections were incubated with ABC-HRP complex (DakoCytomation, Glostrup, Denmark). Binding sites were visualized with diaminobenzidine/hydrogen peroxide, and the slides finally counterstained with hematoxylin.
Statistical analysis
All data are expressed as means ± s.e. (standard error) unless otherwise mentioned. Differences between allogeneic and syngeneic analyzed using Mann-Whitney (U-test). Po0.05 is considered statistically significant. Survival curves were plotted using Kaplan-Meier estimates. All statistical analyses were performed utilizing SPSS ver13. Figure 1a shows that 490% of mice (groups-2 and -4) conditioned with CY (300 mg/kg) and BU (80 or 100 mg/kg) died shortly after transplantation (4-5 days). Meanwhile, all animals in group-3 conditioned with BU-CY (100 and 200 mg/kg, respectively) exhibited severe aGVHD and 80% of these mice died within 10 days after BMT ( Figure 1a ). Syngeneic transplanted mice receiving identical conditioning (group-6) survived until þ 120 days ( Figure 1a were observed in syngeneic transplanted mice. Over 60% of non-transplanted mice, treated with the same doses of BU-CY died within 21 days. During the following data group-1 will be allogeneic and group-5 will be syngeneic whereas group-9 is the control group.
Results
Dose optimization and clinical manifestations of GVHD
Mean body weight
Weight loss is a good indicator of GVHD in mice. 22 All conditioned mice lost weight after chemotherapy and reached the nadir at day þ 3 and þ 7 in the syngeneic and allogeneic setting, respectively (Figure 1e ). Syngeneic transplanted mice started to regain weight from day þ 3 and reached a control level within 18 days. Mean body weight at day þ 5 was 16.5 ± 1.2 and 18.4 ± 1.3 g in group 1 and group 5, respectively (Po0.001).
The allogeneic group continued to lose weight until day þ 7 and the differences between allogeneic and syngeneic groups remained significant until the end of the study (Po0.001) (Figure 1e) . A hunched posture (Figure 1b ) was seen at day þ 7 in the allogeneic group and was correlated with the nadir of weight loss (Po0.001).
Histopathologic evaluation of conditioning and acute GVHD Histopathologic effects of conditioning regimen. At day 0, a histopathological survey of tibial BM showed extensive cellular depletion with few remaining megakaryocytes. The marrow space primarily consisted of blood filled dilated vessels and white adipose cells. The thymus cortex was essentially devoid of thymocytes, whereas the thymic 6 BM and 30 Â 10 6 spleen cells from male C57BL/6 or female BALB/c (allogeneic and syngeneic setting, respectively). Starting from day þ 7 the following GVHD signs were observed: (b) hunch posture, (c) hair loss, (d) skin lesions, ulceration and denuding were the last manifestation 2-3 days before death and (e) weight loss started after conditioning and BMT in allogeneic and syngeneic groups. (E): Allogeneic group, ( ): syngeneic group and (J): control mice. All values are mean ± s.e. for 3-7 animals in each group per time point. Differences were analyzed statistically employing U-test, compared between groups (*Po0.05). medulla was populated by thymocytes. In the spleen, the red pulp showed diminished extramedullarly hematopoiesis. The white pulp was populated with lymphocytes, although cellularity appeared to be decreased. The dorsal skin did not exhibit any major changes, the hair follicles being in the resting telogen stage. No extensive changes were found in the liver. Disturbance of the goblet cell population was seen in colonic mucosa.
Histopathologic effects of GVHD Skin. At day þ 7 allogeneic mice displayed fairly extensive skin changes (Figure 2) . The epidermis of the dorsal skin showed frequent apoptotic figures (Figure 3 ). Small patches of dorsal skin interfollicular epidermis appeared to have lost the basal living cell layers, only the cornified parts persisting. No hypodermal fat layer could be discerned (Figure 2 ). In contrast, syngeneic mice, displayed an essentially intact epidermis, whereas hypodermal fat was seen to a varying extent (Figure 2 ). By day þ 14 syngeneic mice showed a normal morphology, the different stratified epithelia characterized by well ordered layering and maturation. In allogeneic mice, the dorsal epidermis showed well developed interfollicular epidermal hyperplasia, whereas apoptotic figures were mainly localized to hair follicles. At day þ 21, syngeneic mice were essentially normalized (Figure 2) , whereas allogeneic mice, showed features of extensive aGVHD (Figure 2 ). The interfollicular epidermal hyperplasia was extensive and combined with hyperkeratosis, in areas with immature features like hyperparakeratosis. Extensive, but localized ulcerative changes with formation of corneal pustules were frequent. The basal layers showed intercellular edema. Apoptosis was prevalent in the epidermis and dead cells with apoptotic features seen in the hair follicles (Figure 3 ). Dense infiltrates of neutrophilic granulocytes were often extending into hypodermal fat.
Large intestine. By day þ 7, allogeneic mice showed clear evidence of colitis. Crypt structure was changed and increased presence of inflammatory cells noted in the lamina propria (Figure 2) . At day þ 21, crypts were severely disturbed, showing hyperplasia and hyperchromasi, with numerous cells exhibiting apoptotic features (Figure 3) and frequent mitotic figures. In contrast, syngeneic mice exhibited near normal structure and few apoptotic cells (Figures 2 and 3) .
Liver. Hepatocytes were generally smaller in the allogeneic group. Although extramedullar hematopoiesis was seen early, by 3 weeks liver structure was normalized in the syngeneic, the allogeneic transplanted mice primarily showed increased inflammatory infiltrates in the portal triad ( Figure 2 ).
Immunohistochemistry evaluation of affected organ because of aGVHD Both CD3 þ T cells and the activated form of Caspase 3 (aCPP3 þ ) were frequent in liver, skin and colon in the allogeneic setting, only few were detected in syngeneic mice 6 BM plus 30 Â 10 6 splenocyte from male C57BL/6 or female BALB/c (allogeneic and syngeneic settings, respectively). Skin, large intestine and liver were evaluated in both allogeneic and syngeneic transplanted mice at day þ 7 (beginning of GVHD) and þ 21 (established phase of GVHD) after BMT. Apparent histological differences (leukocyte infiltration and architecture changes) between allogeneic and syngeneic transplanted mice at day þ 7 are owing to initiation of GVHD in allogeneic setting. Histological devastation progressed by time and target tissue developed full characteristic of GVHD manifestations.
( Figure 3 ). This clearly demonstrates development of features compatible with aGVHD.
The effects of conditioning and GVHD on myeloid and lymphoid system As shown in Figures 4a and b , treatment with BU-CY induced intensive decreases in the total number of BMC and splenocytes by 95 and 88%, respectively on day 0 when compared with controls. BM and spleen recovered rapidly in the syngeneic recipients to control levels by day þ 14 (Figures 4a and b) . However, in the allogeneic recipients, the recovery of BM and spleen was slow and at day 21 reached 65 and 25%, respectively when compared with control (Figures 4a and b) .
Treatment with BU-CY, decreased the frequency of CD19 þ cells in the BM (Figure 4c ). The frequency of CD19 þ cells returned to normal in the BM at day þ 14 in the syngeneic group, whereas in allogeneic recipients, cells did not increase and gradually disappeared. The same was observed in the spleen (data not shown).
Conditioned animals showed a significant increase in the frequency of CD3 þ cells in the BM that was normalized rapidly (day þ 7) in the syngeneic recipients whereas in the allogeneic recipients, the frequency of CD3 þ cells was higher at all time points when compared with control ( Figure 4d ). In addition 490% of the infiltrated T cells in the allogeneic setting were of donor origin (data not shown). In the spleen, both syngeneic and allogeneic recipients exhibited transient increase at day 0 followed by a significant decrease in the percentage of CD3 þ cells until day þ 14. The frequency of splenic CD3 þ cells continued to decrease in the allogeneic, but not in the syngeneic recipients (Figure 4e ).
The frequency of CD4 þ and CD8 þ T cells increased at day 0 in the spleen (Figures 4f and g ). Splenic CD4 þ and CD8 þ T cells decreased in the syngeneic recipients until day þ 14 and stabilized by day þ 21. In the allogeneic recipients, a sharp decrease in the frequency of splenic CD4 þ T cells maintained until day þ 21. In contrast, the frequency of splenic CD8 þ T cells increased rapidly by day þ 7, followed by a continuous decrease until day þ 21 (Figures 4f and g) . Furthermore, the ratio of splenic CD4 þ /CD8 þ T cells was significantly decreased in both syngeneic and allogeneic recipients by day þ 7 (Figure 4h ). This decrement was greater in the allogeneic group (Po0.05). However, this ratio normalized in the syngeneic by time and continued to decrease in the allogeneic recipients.
Evaluation of engraftment and chimerism in different tissues of allogeneic recipients As shown in Figure 5a , full chimerism (98%) in the BM was observed at day þ 7, which was sustained until day þ 21. The spleen exhibited 80% chimerism at day þ 7, which increased by time and reached to 95% at day þ 21 (Figure 5a ). The pattern of chimerism in the blood was similar to that observed in the BM (data not shown). (f and g) . Seven days after BMT CD4/CD8 ratio (h) in the spleen of allogeneic transplanted mice decreased more than the syngeneic group (Po0.05). Moreover the ratio normalized in syngeneic transplanted mice whereas decrement continued in allogeneic group until the end of the experiment. (E): allogeneic group, ( ): syngeneic group and (J): control mice. All values are mean ± s.e. for 3-7 animals in each group per time point. Differences were analyzed statistically employing U-test, compared between groups (*Po0.05).
Furthermore, at day þ 7, chimerism of CD11b þ and CD3 þ cell populations in the spleen were 95 and 48%, respectively (Figure 5b) . Chimerism increased to reach 98 and 89%, respectively at day þ 21. Although in the allogeneic recipients, reconstitution of B-cells was profoundly depressed ( Figure 4c) ; however, 490% were of donor origin in all tested intervals (not shown).
FISH analysis of the BM and spleen of the syngeneic group (using Y-chromosome) showed 81 and 90% donor cells, respectively at day þ 7. By day þ 21, the chimerism in 6 BM plus 30 Â 10 6 SP cells from male C57BL/6 and female BALB/c (allogeneic and syngeneic setting, respectively). (a) At appointed time points, 5-7 transplanted mice were killed and total chimerism was evaluated in the spleen and BM. BM of recipient showed full donor chimerism (495%) at day þ 7. Chimerism in spleen was about 80% at day þ 7 and reached to 495% at day 21 after allogeneic BMT. (b) Seven days after BMT chimerism of T-lymphocytes (CD3 þ ) and myeloid lineage (CD11b þ ) in the spleen of recipient mice was 50 and 95% respectively and increased to 90% in CD3 þ population and sustained the same range in myeloid population during next 3 weeks after BMT. (c and d) FACS analysis of skin showed that T cells frequency (c) in the skin of allogeneic transplanted mice was higher when compared with that observed in syngeneic group at all evaluated time points. Although more than 90% of infiltrated T cells were of donor origin (d). (e and f) Twenty-one days after BMT, intestinal single cells analysis using FACS showed that donor cells (H-2Kb) are present in the host small intestine (e). Likewise 490% of infiltrating donor cells were T cells (f). (E): Allogeneic group, ( ): syngeneic group and (J): control mice. All values are mean±s.e. for 3-7 animals in each group per time point. Differences were analyzed statistically employing U-test, compared between groups (*Po0.05).
the BM and spleen reached 96 and 88%, respectively and sustained (498%) in both organs to day þ 120.
Profound infiltration of immune cells in the skin and intestine was observed (Figures 2 and 3) . Characterization of infiltrating cells in the skin (Figure 3) showed that in parallel with the progression of GVHD, the frequency of CD3 þ cells increased in allogeneic, but not syngeneic recipients (Figure 5c ). Moreover, analysis of the infiltrating cells demonstrated that the frequency of total and CD3 þ cells in the skin increased by time and 490% of the infiltrating CD3 þ cells were of donor origin at all tested time points (Figure 5d ). In addition, analysis of recipient intestinal cells at day þ 21 showed that over 6% of whole cell populations were of donor origin (Figure 5f ). Moreover 490% of the infiltrating donor cells were T-lymphocytes (Figure 5f ), which might explain the pathophysiology of gut injury due to GVHD. These results are in line with histopathological finding of skin and intestine.
Discussion
In the present investigation, we introduce for the first time a mouse model of aGVHD based on chemotherapy conditioning. During the last three decades, numerous models of aGVHD have been used to explore mechanisms underlying the development of GVHD. 23, 24 Almost all current models use TBI alone as conditioning regimen before HSCT. [25] [26] [27] However, several clinical studies have reported the crucial role of conditioning in the development and severity of aGVHD. 28, 29 On the other hand 450% of patients are conditioned with chemotherapy-based regimens. Unfortunately, scant knowledge about chemotherapy-based conditioning in experimental models is available.
Previous studies have shown that BU treatment with 100-150 mg/kg is sufficient to induce myeloablation and/or full donor chimerism. 30, 31 Thus the lack of donor alloreactivity against host residual cells and/or the high dose of BU may explain the lack of need of CY. In our previous studies, 32, 33 we have shown that similar myeloablative effects of BU were obtained after the administration of BU as i.v. or i.p., therefore, BU was administered i.p. in the present investigation. In our dose finding studies, a dose of 4 Â 20 mg/kg followed by 2 Â 100 mg/kg CY was necessary to reach full donor chimerism. Moreover, increasing the dose of BU or CY or both have resulted in a rapid emergence of aGVHD implying that chemotherapy may have a pivotal role in the severity of aGVHD.
Clinical manifestations and histological changes occurred between day þ 7 and day þ 14, resembled aGVHD described in irradiated animals in allogeneic transplantation. 34, 35 The weight loss is the most well documented manifestation of GVHD in mice. 18, 22, 36 In irradiation-based aGVHD models, it has been shown that the weight loss occurs in a bi-phasic manner, that is, a severe phase culminates on day þ 7 followed by an improvement in the weight until day þ 12 and then a second phase of weight loss commences on day þ 16. 37, 38 Interestingly, in the present model, we observed a bi-phasic pattern in the weight loss. However, the first phase started by a modest weight loss at day þ 3, followed by a severe decrement phase at day þ 7. Stable weight at days þ 10 to þ 14 was followed by a second phase of weight loss at day þ 21. The delay in the occurrence of the second phase of weight loss is probably because of differences in myeloablative and immunosuppressive effects after BU-CY compared with that observed after TBI. The present results add more evidence that different pre-transplant conditioning leads to various organ damage and different toxicity profiles.
Skin, gastrointestinal tract, liver and lymphoid organs are the primary target organs in acute GVHD. 27, 39, 40 Most of the pathological alterations including infiltration of inflammatory cells into the skin, liver and large intestine and the presence of high numbers of apoptotic/necrotic cells in all tested organs were similar to those observed in irradiation-based aGVHD mouse models. [40] [41] [42] Our results confirm that the present model fulfils the criteria of aGVHD including histopathological changes.
The mechanism underlying the development of aGVHD in certain organs is not fully understood. However, in a 3-phase model proposed for the pathogenesis of aGVHD, [43] [44] [45] including phase 1, where the conditioning regimen leads to the initial damage and activation of dendritic cells of the host tissues which provides a condition for the migration and activation of donor T cells to the target organ tissue in phase-2. [43] [44] [45] The importance of donor T cells in target organ pathology has been shown earlier. [46] [47] [48] In a mouse model of GVHD based on irradiation, Baker et al. and Nikolic et al. 47, 48 have reported skin and intestine damage in the allogeneic setting and they showed the presence of T cells in the skin lesion and GI; however, they did not confirm the origin of these cells. In the present investigation both immunohistochemistry and FACS results have shown that donor T cells were found in the skin and intestine. FACS analysis showed that the number of infiltrating cells is correlated with severity of lesions.
Finally, phase 3 (the effector phase) involves a complex cascade of multiple cellular and inflammatory effects that cause severe changes in target organs. [43] [44] [45] Our results showed pathological alterations in skin and large intestine, but not the liver at day 0 which probably is because the liver is highly specialized to detoxify xenobiotics, and that the threshold of BU-CY induced toxicity in the liver is higher than that for skin, large intestine and lymphoid organs. Several studies have shown that donor T cells are activated by recipients/donor antigen-presenting cells in the secondary lymphoid organs such as the spleen, lymph nodes and Peyer's patches. 49, 50 In this study, we have also observed that the frequency of donor T cells (particularly CD8 þ ) is increased dramatically in the spleen at the beginning of aGVHD. Subsequently, by the progression and spreading of GVHD to target organs, the level of donor T cells decreased in the spleen, but increased in the target organs. This data is in agreement with that observed by Panoskaltsis et al. and Beilhack et al. 34, 49 where the authors tracked the trafficking of donor T cells in the host and they showed the importance of secondary lymphoid organs in initiation of GVHD. 50 Moreover Murai et al. 51 and others have shown the higher priority of Peyer's patch rather than the spleen in stimulation and alloreactivation of donor lymphocyte. 52 Our data are contra-dictory to that reported by Clouthier et al. 53 who developed aGVHD in splenectomized mice. This is most likely because other secondary lymphoid organs may compensate for the spleen.
Several studies 54, 55 have shown that in MHC mismatch transplantation, both CD4 þ and CD8 þ alloreactive T cells can induce aGVHD. In the present study, we found an intensive expansion of CD8 þ T cells in the spleen of recipient mice at day þ 7. Moreover, a continuous decrease of the ratio CD4 þ /CD8 þ splenic T cells was observed in these animals. These findings and the presence of high levels of apoptosis in the skin, liver and large intestine suggest that CD8 þ T cells have an important function in the effector phase of aGVHD. BM 56 and secondary lymphoid organs, namely spleen 48, 57 are the first targets for GVHD. BM suppression in allogeneic BMT was reported to be caused by cytotoxic T cells. 58 In our study, the cellularity of BM and spleen were significantly (Po0.05) lower in allogeneic compared with syngeneic group. Van Dijken et al. 59 suggested that GVHD does not affect the BM cellularity of the recipient. However, the authors showed that GVHD decreases the hematopoietic reserve and causes damage to the donor stem cell compartment. In our study the cellularity was altered by GVHD which might be because of the major histocompatibility mismatch used in our model that induced severe GVHD compared with the published study where minor histocompatability was used.
An interesting finding in the present model was that during the development of aGVHD, the frequency of Bcells was considerably decreased in both BM and spleen. These observations imply that during the development of aGVHD, a profound impairment occurs in the B-lymphopoieses, which leads to an acquired B-cell deficiency. Although, to our knowledge, this phenomenon has not been reported in GVHD models, clinical studies have shown that patients with GVHD have a decreased Blymphopoiesis. 60 The underlying mechanisms for the impaired B-lymphopoiesis are not known. However, it has been suggested that this phenomenon occurs as a result of either the production of cytokines from the activated alloreactive T cells or the destruction of stromal cells, which support B-lymphopoiesis. 61 To conclude, the present model has an important function for future studies regarding GVHD immunobiology, evaluation-conditioning regimen toxicity and importantly an animal model for the variety of patients undergoing chemotherapy-based conditioning.
